Partnering with Lycia
The flexibility and modular design of our LYTAC platform enable vast potential to generate high-quality candidates for multiple disease areas in a rapid and efficient manner. To maximize the impact of our work for a broad spectrum of patients, we work with partners to discover and develop new LYTAC therapeutics using the combined forces of scientific and patient insights to guide our joint efforts.
Partnerships in Action
We have an ongoing multi-year research collaboration with Eli Lilly and Company to discover and develop novel targeted protein degraders for up to five targets in areas including immunology and pain.
